top of page
About the Trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
Mechanism of Action:
Duration of Study
~24 Weeks
Phase
3
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvanathan
Study Coordinator
Carrie Harrison/Hannah Harrison
bottom of page